Please login to the form below

Not currently logged in
Email:
Password:

Kymriah

This page shows the latest Kymriah news and features for those working in and with pharma, biotech and healthcare.

EC approves Novartis’ Kymriah for advanced blood cancer

EC approves Novartis’ Kymriah for advanced blood cancer

Kymriah is the first CAR-T cell therapy of its kind approved in the EU for follicular lymphoma. ... The approval of Kymriah in Europe brings patients closer to a potentially definitive therapy, providing us with hope for improved outcomes,” she added.

Latest news

More from news
Approximately 15 fully matching, plus 66 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 18 partially matching documents found.

Latest from PMHub

  • Understanding the evolving CAR-T market

    In August 2017, Novartis made history after receiving FDA approval for Kymriah, the world’s first chimeric antigen receptor T-cell (CAR-T) therapy. ... But, Novartis could not retain a monopoly in for long. After the approval of Kymriah, investors

  • Precision paediatrics: Treating patients with CAR-T

    There are a number of trials being undertaken throughout the world, but the first licensed product, Novartis’ Kymriah, is now available for the treatment of leukaemia and is live at GOSH.

  • Training the next generation of biotech leaders

    In August, Novartis’ revolutionary CAR-T therapy, Kymriah, was approved. This was quickly followed by the approval of Kite’s Yescarta in October. ... Kymriah, which make it into routine practice as a first-line treatment.

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Collected Group

Collected Group is a forward thinking healthcare communication company that supports biopharma and diagnostic companies to engage in more lasting...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...